Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tirofiban. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 known ✓ | P05106 | 20/20 | 1.00 |
| ▸ | ITGA2B known ✓ | P08514 | 20/20 | 1.00 |
| ▸ | ITGAV | P06756 | 2/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tirofiban SCHEMBL3685 | 1.00 | ITGB3 (1.00) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| Tirofiban SCHEMBL17721319 | 1.00 | ITGB3 (1.00) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| Tirofiban SCHEMBL155170 | 0.99 | ITGB3 (0.98) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| Tirofiban SCHEMBL28858023 | 0.99 | ITGB3 (0.98) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| Tirofiban SCHEMBL41327 | 0.99 | ITGB3 (0.98) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| Tirofiban SCHEMBL140366 | 0.98 | ITGB3 (0.96) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| Tirofiban SCHEMBL41325 | 0.98 | ITGB3 (0.96) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| Tirofiban SCHEMBL7388934 | 0.98 | ITGB3 (0.96) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| Tirofiban SCHEMBL41326 | 0.97 | ITGB3 (0.95) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| SCHEMBL13873863 | 0.91 | ITGB3 (0.83) | ITGB3ITGA2BITGAVCHRM2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111100066-A | Tirofiban hydrochloride intermediate and preparation method of Tirofiban hydrochloride | 石药集团恩必普药业有限公司 | 2020-05-05 | — | — | CN | claimed |
| EP-2398482-B1 | METHODS AND COMPOSITIONS FOR INHIBITING CELLULAR PROLIFERATION AND SURGICAL ADHESION | NOVELMED THERAPEUTICS INC (US) | 2017-04-19 | — | — | EP | claimed |
| US-9566297-B2 | Methods and compositions for inhibiting cellular proliferation and surgical adhesion | NOVELMED THERAPEUTICS, INC. (US) | 2017-02-14 | — | — | US | claimed |
| US-8680075-B2 | Methods and compositions for inhibiting cellular proliferation and surgical adhesion | NOVELMED THERAPEUTICS, INC. (US) | 2014-03-25 | — | — | US | claimed |
| EP-1068172-A4 | PLATELET AGGREGATION INHIBITION USING LOW MOLECULAR WEIGHT HEPARIN IN COMBINATION WITH A GP IIb/IIIa ANTAGONIST | MERCK & CO INC (US) | 2006-09-27 | — | — | EP | claimed |
| EP-0859634-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING PLATELET AGGREGATION INHIBITORS | MERCK & CO INC (US) | 2002-02-27 | — | — | EP | claimed |
| EP-1068172-A1 | PLATELET AGGREGATION INHIBITION USING LOW MOLECULAR WEIGHT HEPARIN IN COMBINATION WITH A GP IIb/IIIa ANTAGONIST | Merck & Co., Inc. (US) | 2001-01-17 | — | — | EP | claimed |
| US-6136794-A | ANTICOAGULANTS FOR BLOOD USING HEPARIN | MERCK & CO., INC. (US) | 2000-10-24 | — | — | US | claimed |
| EP-1034256-A1 | ANTICOAGULANT TEST | Merck & Co., Inc. (US) | 2000-09-13 | — | — | EP | claimed |
| US-5972967-A | INTRAVENOUS ADMINISTERING 2-(BUTYLSULFONYLAMINO)-3-(4-(4-(PIPERIDIN-4-YL)BUTOXYPHENYL)PR OPIONIC ACID | MERCK & CO., INC. (US) | 1999-10-26 | — | — | US | claimed |
| US-5965581-A | COMPOSITION OF 2-S-(N-BUTYLSULFONYLAMINO)-3-(4-(4-(PIPERIDIN-4-YL)BUTYLOXY)PHENYL)PROPIONIC ACID, SODIUM CHLORIDE, SODIUM CITRATE DIHYDRATE, AND CITRIC ACID ANHYDROUS, OF SPECIFIC OSMOLALITY; PREVENTS THROMBOSIS | MERCK & CO., INC. (US) | 1999-10-12 | — | — | US | claimed |
| WO-1999038827-A1 | PLATELET AGGREGATION INHIBITION USING LOW MOLECULAR WEIGHT HEPARIN IN COMBINATION WITH A GP IIb/IIIa ANTAGONIST | MERCK & CO., INC. (US) | 1999-08-05 | — | — | WO | claimed |
| EP-0743302-B1 | Sulfonamide fibrinogen receptor antagonists | MERCK & CO INC (US) | 1999-08-04 | — | — | EP | claimed |
| WO-1999019463-A1 | ANTICOAGULANT TEST | MERCK & CO., INC. (US) | 1999-04-22 | — | — | WO | claimed |
| EP-0859634-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING PLATELET AGGREGATION INHIBITORS | Merck & Co., Inc. (US) | 1998-08-26 | — | — | EP | claimed |
| WO-1997015328-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING PLATELET AGGREGATION INHIBITORS | MERCK & CO., INC. (US) | 1997-05-01 | — | — | WO | claimed |
| EP-0478363-B1 | Novel sulfonamide fibrinogen receptor antagonists | MERCK & CO INC (US) | 1997-03-19 | — | — | EP | claimed |
| EP-0743302-A2 | Sulfonamide fibrinogen receptor antagonists | MERCK & CO. INC. (US) | 1996-11-20 | — | — | EP | claimed |
| CN-113527183-A | Tirofiban degradation impurity and preparation method and application thereof | 远大医药（中国）有限公司 | 2021-10-22 | — | — | CN | disclosed |
| WO-1997015328-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING PLATELET AGGREGATION INHIBITORS | MERCK & CO., INC. (US) | 1997-05-01 | — | — | WO | disclosed |